Grail Nears $1 Billion In Series B
Menlo Park-based GRAIL, a startup that is developing blood testing technology for early stage cancer detection, is expecting to close a $1 billion, Series B funding, according to founding investor Illumina. Grail, which raised $100 million in Series A financing in 2016, from Illumina, ARCH Venture Partners, Bezos Expeditions, Bill Gates, Sutter Hill Ventures, and GV (formerly Google Ventures), said the private placement agent for the funding is Goldman Sachs.
posted on Friday, January 6, 2017
Related companies:
GRAIL
Related stories:
> GRAIL Raises $900M For Cancer Detection Efforts
> Grail Gets $300M More For Cancer Detection Testing
> Uber Round Rises To $2.8 Billion
> Report: Yahoo Plans Investment in Snapchat
> Automation Anywhere Finds $250M In Massive Series A, Valued At $1.8 Billion
silicontap.com Home